ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 693

A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy

Niamh P. Quillinan1, Deirdre McIntosh2, Syed Haq2 and Christopher P. Denton1, 1Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 2Daval International Ltd, Eastbourne, East Sussex, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Lung, Scleroderma, systemic sclerosis and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

We have performed a study to explore safety and tolerability of hyperimmune caprine serum (AIMSPRO®) prepared under GMP conditions in established diffuse cutaneous systemic sclerosis (dcSSc). Potential measures of efficacy and biological activity were also examined.

Methods:

A double-blind parallel group placebo controlled clinical trial was performed under clinical trial authorisation with regulatory authorisation and institutional ethical approval. After informed consent, 20 patients with established dcSSc of greater than 3 years duration not receiving immunosuppressive therapy were randomised to receive either active (n=10) or placebo formulation (n=10) by subcutaneous twice weekly injection over 26 weeks. Clinical assessments evaluated over 26 weeks included modified Rodnan skin score (MRSS), pulmonary function indices and HAQ-DI.

Results:

There were no safety concerns during this study. Frequency of adverse events was not different between active and placebo groups; 154 AE occurred in those receiving placebo and 139 AE in the AIMSPRO® treated subjects. The commonest adverse event was minor injection site reaction occurring in 12 subjects. There were 6 SAE in 3 subjects in the placebo group and 4 SAE in 3 subjects receiving active treatment. No SAE was judged treatment related.

Mean (±SD) baseline MRSS for the study cohort was 15.1 ±7.1, with no significant difference between active or placebo groups. Mean skin score fell by 1.4±4.7 units with active treatment but worsened by 2.1±6.4 units on placebo. This difference did not reach statistical significance (p=0.18, unpaired t-test) but more cases on active treatment showed significant improvement of more than 4 units and over 20% of baseline MRSS (5/10) compared with placebo (1/10; p=0.01, Fisher exact test). HAQ-DI (Mean±SD) at baseline was 1.15±0.07 for active and 1.59±0.63 for placebo group and at 26 weeks was 1.24±0.98 for active and 1.56±0.55 for placebo. These changes were not statistically different (p=0.34, unpaired t-test).

Lung function indices (Table 1) showed a trend of benefit for active treatment compared to the placebo group for those variables that reflect respiratory effort (FVC and FEV1). DLco and TLC did not change during the study.

Table 1:

                                     Baseline                   26 weeks        Units                          p-value

                                                                                                                           (unpaired t-test)

FVC     active              2.68±0.76                  2.76±0.69        Litres                       p=0.06

           placebo           3.12±2.96                  2.96±0.92                                         

FEV1   active              1.99±0.45                  2.02±0.44        Litres                       p=0.10

           placebo           2.31±0.66                  2.21±0.66                                         

DLco   active              5.73±1.80                  5.61±1.87        mmol/min/kPA         p=0.36

           placebo           5.99±2.19                  5.67±2.28                                         

Conclusion:

These results demonstrate tolerability and safety of this novel biological agent in established diffuse cutaneous SSc. The value of a placebo treated control group in small clinical trials evaluating skin disease in SSc is confirmed. Potential improvement in MRSS in cases receiving active therapy and trends of improvement for pulmonary function indices suggest that this intervention may be of clinical benefit and warrants further evaluation.


Disclosure:

N. P. Quillinan,
None;

D. McIntosh,

Daval International Ltd.,

5,

Daval Interational Ltd.,

1;

S. Haq,

Daval International Ltd.,

5,

Daval International Ltd.,

1;

C. P. Denton,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-placebo-controlled-phase-ii-study-of-hyperimmune-caprine-serum-in-diffuse-cutaneous-systemic-sclerosis-safety-and-potential-efficacy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology